Literature DB >> 21722955

In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.

Louise Purtell1, Lisa Sze, Georgina Loughnan, Ellie Smith, Herbert Herzog, Amanda Sainsbury, Katharine Steinbeck, Lesley V Campbell, Alexander Viardot.   

Abstract

OBJECTIVE: Prader-Willi syndrome (PWS) is a leading genetic cause of obesity, characterized by hyperphagia, endocrine and developmental disorders. It is suggested that the intense hyperphagia could stem, in part, from impaired gut hormone signaling. Previous studies produced conflicting results, being confounded by differences in body composition between PWS and control subjects.
DESIGN: Fasting and postprandial gut hormone responses were investigated in a cross-sectional cohort study including 10 adult PWS, 12 obese subjects matched for percentage body fat and central abdominal fat, and 10 healthy normal weight subjects.
METHODS: PYY[total], PYY[3-36], GLP-1[active] and ghrelin[total] were measured by ELISA or radioimmunoassay. Body composition was assessed by dual energy X-ray absorptiometry. Visual analog scales were used to assess hunger and satiety.
RESULTS: In contrast to lean subjects (p<0.05), PWS and obese subjects were similarly insulin resistant and had similar insulin levels. Ghrelin[total] levels were significantly higher in PWS compared to obese subjects before and during the meal (p<0.05). PYY[3-36] meal responses were higher in PWS than in lean subjects (p=0.01), but not significantly different to obese (p=0.08), with an additional non-significant trend in PYY[total] levels. There were no significant differences in self-reported satiety between groups, however PWS subjects reported more hunger throughout (p=0.003), and exhibited a markedly reduced meal-induced suppression of hunger (p=0.01) compared to lean or obese subjects.
CONCLUSIONS: Compared to adiposity-matched control subjects, hyperphagia in PWS is not related to a lower postprandial GLP-1 or PYY response. Elevated ghrelin levels in PWS are consistent with increased hunger and are unrelated to insulin levels.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722955     DOI: 10.1016/j.npep.2011.06.001

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  19 in total

1.  Clinical and Molecular Characterization of Prader-Willi Syndrome.

Authors:  G N Sanjeeva; Madhuri Maganthi; Himabindu Kodishala; Rohit Kumar R Marol; Pooja S Kulshreshtha; Elisa Lorenzetto; Jayarama S Kadandale; Uros Hladnik; P Raghupathy; Meenakshi Bhat
Journal:  Indian J Pediatr       Date:  2017-06-29       Impact factor: 1.967

Review 2.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

Review 3.  Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.

Authors:  Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

4.  Changes in levels of peripheral hormones controlling appetite are inconsistent with hyperphagia in leptin-deficient subjects.

Authors:  Sadia Saeed; Paul R Bech; Tayyaba Hafeez; Rabail Alam; Mario Falchi; Mohammad A Ghatei; Stephen R Bloom; Muhammad Arslan; Philippe Froguel
Journal:  Endocrine       Date:  2013-07-04       Impact factor: 3.633

Review 5.  Ghrelin and eating disorders.

Authors:  Deniz Atalayer; Charlisa Gibson; Alexandra Konopacka; Allan Geliebter
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-30       Impact factor: 5.067

Review 6.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

7.  Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.

Authors:  R J Kuppens; G Diène; N E Bakker; C Molinas; S Faye; M Nicolino; D Bernoux; P J D Delhanty; A J van der Lely; S Allas; M Julien; T Delale; M Tauber; A C S Hokken-Koelega
Journal:  Endocrine       Date:  2015-05-20       Impact factor: 3.633

8.  Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model.

Authors:  Juan A Rodriguez; Emily C Bruggeman; Bharath K Mani; Sherri Osborne-Lawrence; Caleb C Lord; Henry F Roseman; Hannah L Viroslav; Prasanna Vijayaraghavan; Nathan P Metzger; Deepali Gupta; Kripa Shankar; Claudio Pietra; Chen Liu; Jeffrey M Zigman
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

9.  Is ghrelin a biomarker of early-onset scoliosis in children with Prader-Willi syndrome?

Authors:  Dibia Liz Pacoricona Alfaro; Gwenaelle Diene; Graziella Pinto; Jean-Pierre Salles; Isabelle Gennero; Sandy Faye; Catherine Molinas; Marion Valette; Catherine Arnaud; Maithé Tauber
Journal:  Orphanet J Rare Dis       Date:  2021-07-08       Impact factor: 4.123

10.  A clinical follow-up of 35 Brazilian patients with Prader-Willi syndrome.

Authors:  Caio Robledo D'Angioli Costa Quaio; Tatiana Ferreira de Almeida; Lilian Maria José Albano; Israel Gomy; Debora Romeo Bertola; Monica Castro Varela; Celia P Koiffmann; Chong Ae Kim
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.